CN114949123A - Medicinal and edible composition as well as preparation method and application thereof - Google Patents

Medicinal and edible composition as well as preparation method and application thereof Download PDF

Info

Publication number
CN114949123A
CN114949123A CN202210589300.2A CN202210589300A CN114949123A CN 114949123 A CN114949123 A CN 114949123A CN 202210589300 A CN202210589300 A CN 202210589300A CN 114949123 A CN114949123 A CN 114949123A
Authority
CN
China
Prior art keywords
parts
powder
leaf powder
medicinal
edible composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202210589300.2A
Other languages
Chinese (zh)
Other versions
CN114949123B (en
Inventor
王磊
黄燕巧
薛强
程鑫颖
吴利苹
冯雪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chenguang Biotech Group Handan Co ltd
Original Assignee
Chenguang Biotech Group Handan Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chenguang Biotech Group Handan Co ltd filed Critical Chenguang Biotech Group Handan Co ltd
Priority to CN202210589300.2A priority Critical patent/CN114949123B/en
Publication of CN114949123A publication Critical patent/CN114949123A/en
Application granted granted Critical
Publication of CN114949123B publication Critical patent/CN114949123B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/52—Juglandaceae (Walnut family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A61K36/605—Morus (mulberry)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/62—Nymphaeaceae (Water-lily family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the technical field of food, health-care food and traditional Chinese medicine, and particularly discloses a medicine-food homologous composition as well as a preparation method and application thereof. The medicinal and edible composition comprises soybean lecithin, inulin, hawthorn powder, fructo-oligosaccharide, green tea powder, tea polyphenol, red yeast rice powder, alfalfa powder, lotus leaf powder, kudzu root powder, mulberry leaf powder and vitamin C, and also particularly comprises roxburgh rose powder, phyllostachys edulis leaf powder and cyclocarya paliurus leaf powder. The composition can realize the effects of preventing and/or assisting in treating hyperuricemia and hyperlipidemia, is safe and effective, and has no toxic or side effect.

Description

Medicinal and edible composition as well as preparation method and application thereof
Technical Field
The invention relates to the technical field of food, health-care food and traditional Chinese medicine, in particular to a medicine-food homologous composition and a preparation method and application thereof.
Background
Hyperuricemia is a disease in which blood uric acid exceeds normal values due to purine metabolic disorder and/or uric acid excretion disorder, and does not clinically manifest any symptoms at the early stage. Under the condition of long-term hyperuricemia, uric acid can be precipitated in joints, soft tissues, cartilages and kidneys in the form of sodium salt, so that organ and tissue lesions of a human body are caused, gout is caused, and serious complications including gouty arthritis, gouty kidney lesions and the like are caused. Therefore, how to effectively reduce uric acid is a major problem for patients with hyperuricemia and gout.
Hyperlipidemia is a systemic disease, and can be divided into primary hyperlipidemia and secondary hyperlipidemia according to the pathogenesis. The damage to the body from the disease is occult, gradual, progressive and systemic. The direct damage of the medicine is to accelerate the atherosclerosis of the whole body, and a large number of research data show that the hyperlipemia is also an independent and important risk factor for cerebral apoplexy, coronary heart disease, myocardial infarction and sudden cardiac death. Hyperuricemia and primary gout are in obvious positive correlation with diseases such as obesity, hyperlipidemia, diabetes, atherosclerosis and the like. From clinical practice, most gout patients have not only high blood uric acid value but also high blood lipid value.
At present, medicaments for treating hyperuricemia mainly comprise febuxostat, allopurinol, colchicine, benzbromarone and the like, and medicaments for treating hyperlipidemia mainly comprise statins, fibrates and the like. The medicines have good curative effect, but a plurality of medicines are easy to generate antagonistic action when being taken simultaneously, in addition, the medicines show certain toxic and side effects in clinic, and great health hidden trouble is brought to patients after long-term use of the medicines. Under the condition, a way for safely and effectively reducing uric acid and blood fat is found from edible materials and new food raw materials which are homologous to each other and are one of the directions for preventing and treating gout, hyperuricemia and hyperlipidemia.
Chinese patent application 'a soybean lecithin red yeast rice alfalfa tea solid beverage and a preparation method thereof' (patent application number: 201911313891.5) discloses an alfalfa tea solid beverage and a preparation method thereof, relates to the technical field of solid beverages, and discloses that the inventive solid beverage has the effect of assisting in reducing blood pressure and blood fat, but no efficacy test or human trial can verify the claimed efficacy, and no teaching or suggestion that the scheme can be expected to realize the reduction of uric acid is given. Therefore, further research on medicinal and edible formulas is needed.
Disclosure of Invention
Aiming at the problems in the prior art, the invention overcomes the defects of high cost and great side effect of the existing treatment method, and one of the purposes of the invention is to provide the composition with the functions of reducing uric acid and blood fat.
In order to achieve the purpose, the technical scheme of the invention is as follows:
a medicinal and edible composition comprises soybean phospholipid, inulin, fructus crataegi powder, fructo-oligosaccharide, green tea powder, tea polyphenols, red rice powder, herba Medicaginis powder, folium Nelumbinis powder, radix Puerariae powder, folium Mori powder and vitamin C, and also comprises fructus Rosae Normalis powder, folium Bambusae powder and cyclocarya paliurus leaf powder.
The soybean lecithin and red yeast rice have the functions of obviously reducing cholesterol, triglyceride and low-density lipoprotein in blood, and can prevent cardiovascular and cerebrovascular diseases and improve hyperlipidemia.
Both fructo-oligosaccharide and inulin belong to prebiotics and are water-soluble dietary fibers. The fructo-oligosaccharide can improve intestinal flora and stimulate intestinal peristalsis, metabolic syndrome is accompanied by most of patients with hyperlipidemia and gout, and the metabolic syndrome can be improved by supplementing dietary fiber, so that the overall metabolic condition of the patients is improved.
Hawthorn fruit is sour, sweet and warm in nature, and enters spleen, stomach and liver meridians. The hawthorn contains effective components such as flavone, triterpene, flavan polymer and rutin, and has good effects of promoting digestion, invigorating stomach, promoting qi circulation, removing blood stasis, increasing coronary flow, reducing blood fat and blood cholesterol concentration, and the like.
The tea polyphenols in green tea can comprehensively regulate blood lipid, especially reduce the contents of serum TG, TC and low density lipoprotein cholesterol. Puerarin in radix Puerariae can inhibit xanthine oxidase, promote uric acid excretion, and reduce serum uric acid level, so as to achieve anti-gout effect. The roxburgh rose and the alfalfa both contain rich flavonoid, polyphenol and other components, have the effects of preventing and treating atherosclerosis and enhancing immunity, and have the obvious effect of reducing blood fat.
Lotus leaves, mulberry and cyclocarya paliurus belong to medicinal and edible food materials. The lotus leaf contains various alkaloids substances such as nuciferine and liensinine, and components such as flavone, polysaccharide and vitamin, and has effects of clearing away summer-heat, lowering blood pressure, and reducing the content of triglyceride and cholesterol in blood serum. Nuciferine and its analogs can reduce serum uric acid level, especially uric acid level caused by increased uric acid content due to consumption of hypoxanthine and nicotinic acid, and can effectively relieve hyperuricemia.
The mulberry leaves contain various active ingredients such as vitamins, flavones, polyphenol, alkaloid, terpenoid, steroid and the like, and have various effects of reducing blood sugar, blood pressure and cholesterol, resisting atherosclerosis, reducing uric acid, preventing and treating gout and the like. Cyclocarya paliurus has multiple health-care functions of reducing blood, blood fat, blood pressure, blood sugar and oxygen.
According to the invention, researches show that the known formula contains various components with prevention, control and relief of ventilation effects, namely fructo-oligosaccharide, inulin, radix puerariae, lotus leaves and mulberry leaves, but the ideal uric acid reduction effect cannot be brought into play actually, but when roxburgh rose powder, phyllostachys edulis leaf powder and cyclocarya paliurus leaf powder which have no obvious uric acid reduction effect are compounded in a specific formula for use, the double effects of reducing blood fat and reducing uric acid are achieved unexpectedly. In addition, inulin in the formula provided by the invention also has synergistic effect with other components, and has the effects of further reducing uric acid and reducing blood fat. The invention integrally expands the effect of the medicinal and edible composition and avoids the side effect of the traditional western medicine.
The medicinal and edible composition simultaneously combines soybean lecithin, composite prebiotics, various medicinal and edible raw materials and new food raw materials, can improve the environment and intestinal metabolic capacity in a body, has the effects of enhancing heat clearing and damp clearing, reducing phlegm and heat, promoting diuresis and softening hard masses, clearing heat and dredging collaterals, balancing yin and yang, improving body excretion and other functions, can reduce blood fat, promote purine to be discharged out of the body along with urine, comprehensively regulate blood uric acid concentration, and has good effects of reducing uric acid and preventing gout.
The invention integrates various plant essences, is rich in terpenoids, flavonoids and phenolic acid compounds, can remove cholesterol and fat in human blood, further reduces uric acid and blood fat by reducing the enzyme activities of fatty acid synthetase, xanthine oxidase and the like, and has the synergistic effect of complementing functional components in human bodies to make up for deficiencies of others.
Preferably, the mass ratio of the roxburgh rose powder to the phyllostachys edulis leaf powder to the cyclocarya paliurus leaf powder is (4-6.5): (3-7): (2.5-6).
More preferably, the mass ratio of the roxburgh rose powder to the phyllostachys edulis leaf powder to the cyclocarya paliurus leaf powder is 6.5:7:6, so that better uric acid and lipid-lowering effects are achieved.
The medicinal and edible composition comprises the following components in parts by weight:
10-35 parts of soybean lecithin, 5-30 parts of inulin, 5-20 parts of hawthorn powder, 5-20 parts of fructo-oligosaccharide, 2-8 parts of green tea powder, 1-8 parts of tea polyphenol, 4-6.5 parts of roxburgh rose powder, 2-8 parts of red yeast rice powder, 1.5-10 parts of alfalfa powder, 1-10 parts of lotus leaf powder, 2-15 parts of kudzu root powder, 1-10 parts of mulberry leaf powder, 3-7 parts of lophatherum gracile powder, 2.5-6 parts of cyclocarya paliurus leaf powder and 0.1-1.5 parts of vitamin C;
preferably, the composition comprises the following components in parts by weight:
20 parts of soybean lecithin, 12 parts of inulin, 10 parts of hawthorn powder, 10 parts of fructo-oligosaccharide, 6 parts of green tea powder, 6 parts of tea polyphenol, 6.5 parts of roxburgh rose powder, 6 parts of red yeast rice powder, 7 parts of alfalfa powder, 7 parts of lotus leaf powder, 10 parts of kudzuvine root powder, 7 parts of mulberry leaf powder, 7 parts of light bamboo leaf powder, 6 parts of cyclocarya paliurus leaf powder, 0.4 part of vitamin C, 0.15 part of stevioside, 0.2 part of silicon dioxide and 4 parts of microcrystalline cellulose.
The medicinal and edible composition also comprises a sweetening agent, a glidant and an anticaking agent.
Preferably, the sweetener is stevioside, the glidant is silicon dioxide, and the anticaking agent is microcrystalline cellulose.
The medicinal and edible composition comprises the following components in parts by weight: 0.1-0.3 part of sweetening agent, 0.1-2 parts of glidant and 3-13 parts of anticaking agent.
The invention also provides a method for preparing the medicinal and edible composition, which comprises the step of mixing the components.
As a specific embodiment, the preparation method of the medicinal and edible composition comprises the following steps:
s1: weighing soybean phospholipid, inulin, hawthorn powder, fructo-oligosaccharide, green tea powder, tea polyphenol, roxburgh rose powder, red yeast rice powder, alfalfa powder, lotus leaf powder, kudzu root powder, mulberry leaf powder, phyllostachys edulis leaf powder, cyclocarya paliurus leaf powder, vitamin C, microcrystalline cellulose, silicon dioxide and stevioside according to the weight part ratio.
S2: and putting the weighed materials into equipment, fully stirring and mixing for 15-25min, and uniformly mixing.
S3: and quantitatively subpackaging the stirred materials by using an automatic filling machine to prepare the solid beverage. Or adding other edible adjuvants to make into liquid beverage, tablet, granule or capsule.
The invention also provides application of the medicinal and edible composition in preparation of uric acid and/or blood fat reducing products.
In the invention, the product is health food, functional food or Chinese medicinal preparation; preferably, the product is in the form of solid beverage, liquid beverage, tablet, granule or capsule;
and/or the product also comprises food additives and/or edible auxiliary materials (which can be prepared by the conventional production process).
The powder prepared by the formula has the advantages of stable property, convenience in storage and carrying, rich sour and sweet taste, high bioavailability, wide audience and the like, and has good development and application prospects.
The invention has the beneficial effects that:
the invention provides a medicinal and edible composition with the functions of reducing uric acid and reducing blood fat, so that the prevention and/or auxiliary treatment of hyperuricemia and hyperlipidemia can be realized. The composition adopts medicinal and edible raw materials, can relieve the symptoms of gout and hyperlipidemia by specific raw material proportion, has the effects of inducing diuresis to reduce edema, clearing liver and benefiting gallbladder, is safe and free of toxic and side effects, can be used as common food and also can be used as medicine, is beneficial to preventing and relieving various symptoms caused by high uric acid and blood fat, can be used for a long time, has rich taste and wide audience, and has good development and application prospects.
Detailed Description
Preferred embodiments of the present invention will be described in detail with reference to the following examples. It is to be understood that the following examples are given for illustrative purposes only and are not intended to limit the scope of the present invention. Various modifications and alterations of this invention will become apparent to those skilled in the art without departing from the spirit and scope of this invention.
The experimental procedures used in the following examples are all conventional procedures unless otherwise specified. Materials, reagents and the like used in the following examples are commercially available or can be prepared by a method conventional in the art unless otherwise specified.
Example 1
The embodiment provides a solid beverage preparation of a composition with the effects of reducing uric acid and blood fat, which comprises the following raw materials in parts by weight: 10 parts of soybean lecithin, 5 parts of inulin, 5 parts of hawthorn powder, 5 parts of fructo-oligosaccharide, 2 parts of green tea powder, 1 part of tea polyphenol, 4 parts of roxburgh rose powder, 2 parts of red yeast rice powder, 1.5 parts of alfalfa powder, 1 part of lotus leaf powder, 2 parts of kudzu root powder, 1 part of mulberry leaf powder, 3 parts of lophatherum gracile powder, 2.5 parts of cyclocarya paliurus leaf powder, 0.1 part of vitamin C, 0.1 part of stevioside, 0.1 part of silicon dioxide and 3 parts of microcrystalline cellulose.
The preparation method of the solid beverage preparation of the composition with the effects of reducing uric acid and blood fat comprises the following steps:
s1: weighing the raw materials of the composition according to the weight part ratio.
S2: and putting the weighed materials into equipment, and fully stirring and uniformly mixing.
S3: quantitatively subpackaging the stirred materials by an automatic filling machine to prepare the solid beverage of the composition with the functions of reducing uric acid and blood fat.
Example 2
The embodiment provides a composition of the invention, which is composed of the following components in parts by weight: 20 parts of soybean lecithin, 12 parts of inulin, 10 parts of hawthorn powder, 10 parts of fructo-oligosaccharide, 6 parts of green tea powder, 6 parts of tea polyphenol, 6.5 parts of roxburgh rose powder, 6 parts of red yeast rice powder, 7 parts of alfalfa powder, 7 parts of lotus leaf powder, 10 parts of kudzuvine root powder, 7 parts of mulberry leaf powder, 7 parts of light bamboo leaf powder, 6 parts of cyclocarya paliurus leaf powder, 0.4 part of vitamin C, 0.15 part of stevioside, 0.2 part of silicon dioxide and 4 parts of microcrystalline cellulose.
See example 1 for a method of preparation thereof.
Example 3
The embodiment provides a composition of the invention, which is composed of the following components in parts by weight: 35 parts of soybean lecithin, 30 parts of inulin, 20 parts of hawthorn powder, 20 parts of fructo-oligosaccharide, 8 parts of green tea powder, 8 parts of tea polyphenol, 6.5 parts of roxburgh rose powder, 8 parts of red yeast rice powder, 10 parts of alfalfa powder, 10 parts of lotus leaf powder, 15 parts of kudzu root powder, 10 parts of mulberry leaf powder, 7 parts of lophatherum gracile powder, 6 parts of cyclocarya paliurus leaf powder, 1.5 parts of vitamin C, 0.3 part of stevioside, 2 parts of silicon dioxide and 13 parts of microcrystalline cellulose.
See example 1 for a method of preparation thereof.
Comparative example 1
The comparative example adopts 12 active ingredients recorded in the Chinese patent application 'a soybean lecithin red yeast rice alfalfa tea solid beverage and a preparation method thereof (patent application number: 201911313891.5)', and prepares the solid beverage by adopting the proportion and the method in the embodiment 2 of the invention.
The specific formula is as follows:
20 parts of soybean lecithin, 12 parts of inulin, 10 parts of hawthorn powder, 10 parts of fructo-oligosaccharide, 6 parts of green tea powder, 6 parts of tea polyphenol, 6 parts of red yeast rice powder, 7 parts of alfalfa powder, 7 parts of lotus leaf powder, 10 parts of kudzu root powder, 7 parts of mulberry leaf powder, 0.4 part of vitamin C, 0.15 part of stevioside, 0.2 part of silicon dioxide and 4 parts of microcrystalline cellulose.
Comparative example 2
This comparative example provides a composition (solid beverage) which is substantially the same as the formulation and preparation method of example 2 except that the amounts of 3 components of the roxburgh rose powder, the phyllostachys edulis leaf powder and the cyclocarya paliurus leaf powder added in the formulation were changed to 6.5 parts, 2.5 parts and 2 parts in this order, and the other components and the compounding ratio were kept unchanged.
Comparative example 3
This comparative example provides a composition (solid beverage) which is substantially the same as the formulation and preparation method of example 2 except that the amounts of 3 components of the roxburgh rose powder, the phyllostachys edulis leaf powder and the cyclocarya paliurus leaf powder added in the formulation were changed to 7.5 parts, 2.5 parts and 8 parts in this order, and the other components and the compounding ratio were kept unchanged.
Comparative example 4
This comparative example provides a composition (solid beverage) which is substantially the same as the formulation and preparation method of example 1 except that cyclocarya paliurus leaf powder is not added to the formulation and the other components and proportions are the same as those of example 1.
Comparative example 5
This comparative example provides a composition (solid beverage) having substantially the same formulation and preparation method as in example 1 except that cyclocarya paliurus leaf powder and lophatherum gracile powder were not added to the formulation, and the other components and proportions were kept the same as in example 1.
Comparative example 6
This comparative example provides a solid beverage whose composition was only a sample of roxburgh rose powder.
Comparative example 7
This comparative example provides a solid beverage whose composition was only a thin bamboo leaf powder sample.
Comparative example 8
This comparative example provides a solid beverage whose composition is only a cyclocarya paliurus leaf powder sample.
Comparative example 9
This comparative example provides a composition (solid beverage) which is substantially the same as the formulation and preparation method of example 2 except that no inulin was added to the formulation and the other components and proportions were consistent with example 2.
Comparative example 10
This comparative example provides a composition (solid beverage) which is substantially the same as the formulation and preparation method of example 1 except that no mulberry leaf powder was added to the formulation and the other components and compounding ratio were kept in agreement with example 1.
Comparative example 11
This comparative example provides a composition (solid beverage) prepared according to the method of example 1 of patent application No. 201911313891.5.
Experimental example 1 animal efficacy verification test
This experimental example was conducted to test the effects of the solid beverages obtained in the above examples and comparative examples. The method comprises the following specific steps:
the hyperuricemia model is established on experimental animals: SD rats, male, 6-8 weeks old, 200 ± 20g, 20, purchased from sbefu (beijing) biotechnology limited, license number: SCXK (Jing) 2019-; maintaining the feed and padding.
Adaptation of experimental animals: SPF male SD rats 20, weight 180-: the temperature is 20-26 ℃, the humidity is 40-70%, the illumination and the darkness are alternated 12h each day, and the animals can drink water freely. Putting into quarantine room for adaptive breeding for 7 d. The rats bred for 7d are randomly divided into a blank group, a modeling 1 group, a modeling 2 group and a modeling 3 group according to the body weight.
Evaluation of uric acid lowering efficacy of the experimental samples of each group (examples and comparative examples) the experimental animals were formally tested: SD rats, male, 6-8 weeks old, 200 + -20 g, 80, were acclimatized under the same conditions as described above in the pre-experiment established for hyperuricemia model for 7 days, and then randomly divided into a blank group, a model group, examples 1-3, and comparative examples 1-11 by weight, each group consisting of 5 rats.
The detection method of the renal function index and the blood fat process of the rat comprises the following steps: after administration of each group of experimental rats, collecting blood of fundus venous plexus of the experimental rats on the 30d day after administration, placing plasma samples for 1-2h at room temperature, centrifuging at 4 ℃ (10min, 215Xg) to obtain serum, measuring change conditions of uric acid content in the serum by using a biochemical analyzer, and detecting change conditions of creatinine, total cholesterol and triglyceride in the serum by using a biochemical kit.
Other index detection methods of hyperuricemia rats comprise the following steps: liver XOD, ADA viability assay: after administration for 30 days, after anaesthesia and sacrifice of the rats, rat liver tissue was accurately weighed out in mass (g): volume (mL) as 1: adding 0.9% physiological saline at ratio 9, mechanically homogenizing in ice water bath, centrifuging at 4 deg.C (10min, 215Xg), and collecting supernatant for determination. The viability of XOD and ADA in liver tissue was determined using a biochemical analyzer.
Modeling a rat with hyperuricemia: according to the literature (1, Chenlinjun, Yan, Wudi, etc.. the establishment of rat models of hyperuricemia and complications thereof [ J ]. Chinese experimental animal science, 2020,28(4): 510) 516 [2] Shihui, Lixiang, Huanglivin, etc.. an improvement and effect evaluation research of hyperuricemia rat model induction method [ J ]. Chinese journal of application physiology, 2020,36(3): 223:. 227.), adenine and potassium oxonate are selected as molding drugs, a preliminary experiment is designed, the dosage and the molding time of the molding drugs are groped, and the grouping and the dosing conditions of animals in the preliminary experiment are shown in Table 1.
TABLE 1
Figure BDA0003664413160000091
Test data and analysis:
the change conditions of the uric acid and urea levels of rats in the administration process are shown in table 2, and after 7 days of administration, the uric acid and urea levels of rats in each model group are increased compared with those in a blank group, but the levels are almost not significant (P is less than 0.05); after 14 days of administration, the uric acid and urea levels of the low and medium dose groups are remarkably increased compared with those of a blank control group (P is less than 0.05); after 35 days of administration, the uric acid level of rats in each model group is still significantly increased compared with that in the blank group (P < 0.05).
TABLE 2
Figure BDA0003664413160000092
Figure BDA0003664413160000101
In the table, "+" indicates significance P < 0.05 from blank group.
According to the results of preliminary experiments, it was confirmed that the molding was carried out by administering adenine (administration amount: 100 mg/kg. BW. d) and oteracil potassium (administration amount: 500 mg/kg. BW. d) in combination for 14 days and then starting the administration by gavage after the molding was successful. The administration mode of each group of experimental rats is shown in table 3.
TABLE 3
Figure BDA0003664413160000102
Figure BDA0003664413160000111
Test data and analysis:
the changes of the kidney function index of the rat are shown in Table 4. Compared with a blank group, the levels of uric acid and creatinine of rats in the model group are remarkably increased (P is less than 0.05), which indicates that a rat hyperuricemia model is successfully constructed, and after the rats are administrated for 30 days, the levels of uric acid and creatinine in the examples 1, 2 and 3 are remarkably reduced (P is less than 0.05) compared with the uric acid in the model group and remarkably reduced (P is less than 0.05) compared with the creatinine in the model group, which indicates that the composition has the effect of remarkably reducing uric acid, and the combined components have the synergistic effect on reducing uric acid. The uric acid of the comparative examples 1, 2, 3, 4 and 5 is reduced, but the uric acid is not significant, which shows that the roxburgh rose powder, the phyllostachys pubescens leaf powder and the cyclocarya paliurus leaf powder can reduce the uric acid only under specific matching. The uric acid is not reduced in comparative examples 6, 7 and 8, which shows that the uric acid can not be reduced by using the roxburgh rose powder, the phyllostachys pubescens leaf powder and the cyclocarya paliurus leaf powder alone. Comparative examples 9, 10 and 11 all showed a reduction but no significant difference, indicating that the combination of inulin and mulberry leaf powder with other components in the composition also plays a role in ensuring the uric acid reducing effect.
TABLE 4
Figure BDA0003664413160000112
Figure BDA0003664413160000121
In the table, "#" indicates significance P < 0.05 from the blank group, and "#" indicates significance P < 0.05 from the model group.
The changes of rat adenosine deaminase and xanthine oxidase are shown in Table 5, and the data show that the composition can realize the regulation of the rat with high uric acid by regulating the activity of ADA and XOD enzyme. Compared with the blank group, the adenosine deaminase and xanthine oxidase activities of the model group are obviously increased (P < 0.05), and the adenosine deaminase and xanthine oxidase activities of the examples 1, 2 and 3 are obviously reduced (P < 0.05) compared with the model group. In contrast, the adenosine deaminase and xanthine oxidase activities of comparative examples 1, 2, 3, 5, 6, 7, 9, 10 and 11 were decreased without significant difference compared to the model group. Comparative examples 4 and 8 are poor in use effect.
TABLE 5
Figure BDA0003664413160000122
Figure BDA0003664413160000131
In the table, "#" indicates significance P < 0.05 from the blank group, and "#" indicates significance P < 0.05 from the model group.
The change of total cholesterol and triglyceride content in rats is shown in Table 6. Compared with a blank group, the contents of total cholesterol and triglyceride of the model group rats are obviously increased (P < 0.05), which indicates that the rat hyperlipidemia model is successfully constructed, after the rats are administrated for 30 days, the TC contents of the example 1, the example 2 and the example 3 are obviously reduced compared with the model group (P < 0.05), the TC contents of the comparative examples 1-11 are not obviously reduced, the TG contents of the example 1, the example 2 and the example 3 are obviously reduced compared with the model group (P < 0.05), and the rest comparative examples 1-11 are not obviously different compared with the model group, which indicates that the composition of the invention has the effect of obviously reducing the total cholesterol and triglyceride in the blood of the hyperlipidemic rats under the specific component combination proportion.
TABLE 6
Group of Total Cholesterol content (TC) Triglyceride content (TG)
Blank group 3.04±0.18 1.19±0.14
Model set 5.23±0.42* 1.64±0.31*
Example 1 4.31±0.25# 1.30±0.09#
Example 2 4.01±0.32# 1.28±0.23#
Example 3 4.28±0.31# 1.34±0.19#
Comparative example 1 4.84±0.23 1.66±0.57
Comparative example 2 4.78±0.42 1.59±0.26
Comparative example 3 4.49±0.18 1.51±0.24
Comparative example 4 4.78±0.42 1.56±0.31
Comparative example 5 4.85±0.22 1.48±0.23
Comparative example 6 5.12±0.38 1.60±0.23
Comparative example 7 5.20±0.25 1.59±0.57
Comparative example 8 5.15±0.36 1.59±0.48
Comparative example 9 4.61±0.15 1.56±0.57
Comparative example 10 4.52±0.12 1.55±0.23
Comparative example 11 5.13±0.31 1.51±0.44
In the table, "#" indicates significance P < 0.05 from the blank group, and "#" indicates significance P < 0.05 from the model group.
Human body trial test:
the composition prepared in example 2 is used as a sample to be tested, and 20 patients suffering from hyperlipidemia and hyperuricemia (triglyceride is higher than 2mmoL/L, and blood uric acid detection value is higher than 450 mu moL/L) are gathered for product testing.
The trial method comprises the following steps: 1 dose of warm water is taken each time, 15g is taken each time, 1 time in the morning and evening, and the dose is continuously taken for 45 days. During taking, sufficient water is drunk to limit the ingestion of high-purine foods such as animal viscera, seafood and the like, and no wine or spicy stimulating food is drunk.
And (3) observation indexes are as follows: the change in blood uric acid level and triglyceride level of the patients before and after 45 days of administration was observed.
The mean values of blood uric acid level and triglyceride level in patients before and after administration are shown in Table 7. Wherein, 20 testers continuously test for 45 days, the uric acid level in blood is completely recovered to a normal value, and the triglyceride level is recovered to the normal value in 18 cases. In this trial, the effective rate of reducing uric acid (the ratio of the testers recovering the normal value to the total testers) is 100%, the effective rate of reducing blood fat is 90%, and the testers feed back, so that the joint pain symptom caused by hyperuricemia is relieved after the composition is taken. No allergy and other adverse reactions are observed in the trial process.
TABLE 7
Figure BDA0003664413160000141
Human trials show that the solid beverage prepared from the composition has the effect of reducing uric acid and triglyceride, and has a good effect of adjuvant therapy of hyperlipidemia and gout.
Although the invention has been described in detail hereinabove with respect to a general description and specific embodiments thereof, it will be apparent to those skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, it is intended that all such modifications and alterations be included within the scope of this invention as defined in the appended claims.

Claims (10)

1. A medicinal and edible composition comprises soybean lecithin, inulin, hawthorn powder, fructo-oligosaccharide, green tea powder, tea polyphenol, red yeast rice powder, alfalfa powder, lotus leaf powder, kudzu root powder, mulberry leaf powder and vitamin C, and is characterized by also comprising roxburgh rose powder, phyllostachys pubescens leaf powder and cyclocarya paliurus leaf powder.
2. The medicine and food homologous composition according to claim 1, wherein the mass ratio of the roxburgh rose powder, the phyllostachys edulis leaf powder and the cyclocarya paliurus leaf powder is (4-6.5): (3-7): (2.5-6).
3. The medicinal and edible composition as claimed in claim 2, wherein the mass ratio of the roxburgh rose powder, the phyllostachys edulis leaf powder and the cyclocarya paliurus leaf powder is 6.5:7: 6.
4. The medicinal and edible composition as claimed in any one of claims 1-3, which comprises, in parts by weight:
10-35 parts of soybean lecithin, 5-30 parts of inulin, 5-20 parts of hawthorn powder, 5-20 parts of fructo-oligosaccharide, 2-8 parts of green tea powder, 1-8 parts of tea polyphenol, 4-6.5 parts of roxburgh rose powder, 2-8 parts of red yeast rice powder, 1.5-10 parts of alfalfa powder, 1-10 parts of lotus leaf powder, 2-15 parts of kudzu root powder, 1-10 parts of mulberry leaf powder, 3-7 parts of lophatherum gracile powder, 2.5-6 parts of cyclocarya paliurus leaf powder and 0.1-1.5 parts of vitamin C;
preferably, the composition comprises the following components in parts by weight:
20 parts of soybean lecithin, 12 parts of inulin, 10 parts of hawthorn powder, 10 parts of fructo-oligosaccharide, 6 parts of green tea powder, 6 parts of tea polyphenol, 6.5 parts of roxburgh rose powder, 6 parts of red yeast rice powder, 7 parts of alfalfa powder, 7 parts of lotus leaf powder, 10 parts of kudzuvine root powder, 7 parts of mulberry leaf powder, 7 parts of light bamboo leaf powder, 6 parts of cyclocarya paliurus leaf powder, 0.4 part of vitamin C, 0.15 part of stevioside, 0.2 part of silicon dioxide and 4 parts of microcrystalline cellulose.
5. The medicinal and edible composition as claimed in any one of claims 1-4, which further comprises a sweetener, a glidant and an anti-caking agent.
6. The medicinal and edible composition as claimed in claim 5, wherein the sweetener is stevioside, the glidant is silicon dioxide, and the anti-caking agent is microcrystalline cellulose.
7. The medicinal and edible composition as claimed in claim 5 or 6, which comprises the following components in parts by weight: 0.1-0.3 part of sweetening agent, 0.1-2 parts of glidant and 3-13 parts of anticaking agent.
8. A method for preparing the medicinal and edible composition as defined in any one of claims 1-7, which comprises the step of mixing the components.
9. Use of the medicinal and edible composition as defined in any one of claims 1-7 in the preparation of uric acid-lowering and/or blood lipid-lowering products.
10. The use according to claim 9, wherein the product is a health food, a functional food or a pharmaceutical preparation; preferably, the product is in the form of a solid beverage, a liquid beverage, a tablet, a granule or a capsule.
CN202210589300.2A 2022-05-26 2022-05-26 Composition, and preparation method and application thereof Active CN114949123B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210589300.2A CN114949123B (en) 2022-05-26 2022-05-26 Composition, and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210589300.2A CN114949123B (en) 2022-05-26 2022-05-26 Composition, and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN114949123A true CN114949123A (en) 2022-08-30
CN114949123B CN114949123B (en) 2024-02-06

Family

ID=82956406

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210589300.2A Active CN114949123B (en) 2022-05-26 2022-05-26 Composition, and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN114949123B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107050324A (en) * 2017-01-26 2017-08-18 赵杏珍 A kind of integration of drinking and medicinal herbs Chinese medicine function health toxin expelling drink for preventing and treating gout and three high drop
CN110959710A (en) * 2019-12-19 2020-04-07 米昌锋 Soybean lecithin red yeast rice alfalfa tea solid beverage and preparation method thereof
CN113142352A (en) * 2021-04-08 2021-07-23 贵州贝因特生物技术有限公司 Preparation method of roxburgh rose and cyclocarya paliurus instant tea

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107050324A (en) * 2017-01-26 2017-08-18 赵杏珍 A kind of integration of drinking and medicinal herbs Chinese medicine function health toxin expelling drink for preventing and treating gout and three high drop
CN110959710A (en) * 2019-12-19 2020-04-07 米昌锋 Soybean lecithin red yeast rice alfalfa tea solid beverage and preparation method thereof
CN113142352A (en) * 2021-04-08 2021-07-23 贵州贝因特生物技术有限公司 Preparation method of roxburgh rose and cyclocarya paliurus instant tea

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
陈烨: "淡竹叶化学成分与药理作用研究进展", 《亚太传统医药》 *

Also Published As

Publication number Publication date
CN114949123B (en) 2024-02-06

Similar Documents

Publication Publication Date Title
CN102670864B (en) Medicine composition with antioxidant function for treating cardiovascular and cerebrovascular diseases and sugar diabetes
CN101277710B (en) Antiobesity composition
CN109674958B (en) Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof
CN110075216B (en) Food composition with auxiliary blood fat reducing, weight losing and liver protecting effects and preparation method, preparation and application thereof
CN102920743A (en) Application of spirulina in preparation of anti-hyperuricemia and anti-uarthritis medicine or health-care food
CN105031042A (en) Medicinal composition having weight-loss function and application of medicinal composition
WO2013087023A1 (en) Natural weight reduction health composition and application thereof
CN105055855B (en) With Chinese medicine composition for improving sleep, strengthen immunity effect and its preparation method and application
CN104857154A (en) Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor
CN109620948A (en) The full nature cell Opsonizing method of high lithemia/gout
CN103736071B (en) A kind of composition with auxiliary hyperglycemic effect and application thereof, preparation method
CN1839702A (en) Compound Gynostemma pentaphylla tea for assisting invigorating brain and heart and its preparation method
CN103690819A (en) Traditional Chinese medicinal composition capable of preventing and treating cardiovascular and cerebrovascular diseases and with weight reducing function
CN103920140B (en) A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation
CN108420890B (en) Composition with blood fat reducing effect and preparation method thereof
KR101511364B1 (en) Herbal Extract Composition for Prevention or Treatment of Obesity and Metabolic Syndrome Using Herbal Extract
CN110051817A (en) A kind of Chinese traditional medicine composition and its application reducing uric acid
CN114949123B (en) Composition, and preparation method and application thereof
CN108450941A (en) A kind of dietary composition adjusting lipid metaboli
CN108379455B (en) Uric acid reducing composition
CN115607596B (en) Health wine with uric acid reducing effect and preparation method thereof
CN109731089A (en) A kind of composition and its preparation method and application adjusting liver-stomach disharmony
CN112717078B (en) Traditional Chinese medicine composition, preparation thereof, preparation method and application
CN114246337B (en) Composition for strengthening spleen, eliminating dampness and losing weight as well as preparation method and application thereof
JP2006213607A (en) Uric acid value-decreasing agent

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant